CDTX
Cidara Therapeutics, Inc. [CDTX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CDTX Stock Summary
Top 10 Correlated ETFs
CDTX
Top 10 Correlated Stocks
CDTX
In the News
CDTX Financial details
Company Rating
Buy
Market Cap
73.4M
Income
-31.37M
Revenue
56.54M
Book val./share
0.09
Cash/share
0.54
Dividend
-
Dividend %
-
Employees
73
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-2.35
Forward P/E
-
PEG
0.44
P/S
1.28
P/B
8.99
P/C
1.35
P/FCF
-2.84
Quick Ratio
1.45
Current Ratio
1.62
Debt / Equity
0.54
LT Debt / Equity
0.41
-
-
EPS (TTM)
-0.39
EPS next Y
-
EPS next Q
-
EPS this Y
-48.81%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
67.03%
EPS Q/Q
-35.36%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
21.74%
Inst Trans
0.65%
ROA
-48%
ROE
-259%
ROC
-1.14%
Gross Margin
99%
Oper. Margin
-56%
Profit Margin
-54%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.593-1.48
52W High
-
52W Low
-
RSI
43
Rel Volume
0.36
Avg Volume
695.76K
Volume
248.6K
Perf Week
-20.67%
Perf Month
6.87%
Perf Quarter
-9.72%
Perf Half Y
-22.35%
-
-
-
-
Beta
1.012
-
-
Volatility
0.06%, 0.14%
Prev Close
1.07%
Price
0.7299
Change
0.95%
CDTX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.72 | 0.29 | 0.95 | 0.92 | |
| Net income per share | -2.35 | -1.38 | -1.74 | -0.84 | -0.43 | |
| Operating cash flow per share | -2.26 | -0.98 | -1.31 | -0.48 | -0.41 | |
| Free cash flow per share | -2.26 | -0.98 | -1.31 | -0.48 | -0.41 | |
| Cash per share | 2.97 | 2.07 | 0.86 | 1.19 | 0.47 | |
| Book value per share | 2.35 | 1.3 | 0.26 | 0.41 | -0.04 | |
| Tangible book value per share | 2.35 | 1.3 | 0.26 | 0.41 | -0.04 | |
| Share holders equity per share | 2.35 | 1.3 | 0.26 | 0.41 | -0.04 | |
| Interest debt per share | 0.42 | 0.41 | 0.19 | 0.1 | 0.02 | |
| Market cap | 59.09M | 111.72M | 83.11M | 66.62M | 52.83M | |
| Enterprise value | -5.55M | 63.17M | 55.16M | 9.4M | 21.42M | |
| P/E ratio | -1 | -2.79 | -1.15 | -1.52 | -1.77 | |
| Price to sales ratio | 0 | 5.34 | 6.89 | 1.34 | 0.82 | |
| POCF ratio | -1.04 | -3.92 | -1.53 | -2.64 | -1.86 | |
| PFCF ratio | -1.04 | -3.91 | -1.52 | -2.64 | -1.85 | |
| P/B Ratio | 1 | 2.95 | 7.76 | 3.09 | -18.19 | |
| PTB ratio | 1 | 2.95 | 7.76 | 3.09 | -18.19 | |
| EV to sales | 0 | 3.02 | 4.57 | 0.19 | 0.33 | |
| Enterprise value over EBITDA | 0.08 | -1.5 | -0.77 | -0.22 | -0.72 | |
| EV to operating cash flow | 0.1 | -2.21 | -1.01 | -0.37 | -0.75 | |
| EV to free cash flow | 0.1 | -2.21 | -1.01 | -0.37 | -0.75 | |
| Earnings yield | -1 | -0.36 | -0.87 | -0.66 | -0.56 | |
| Free cash flow yield | -0.96 | -0.26 | -0.66 | -0.38 | -0.54 | |
| Debt to equity | 0.17 | 0.31 | 0.74 | 0.23 | -0.45 | |
| Debt to assets | 0.13 | 0.17 | 0.13 | 0.07 | 0.03 | |
| Net debt to EBITDA | 0.96 | 1.15 | 0.39 | 1.35 | 1.06 | |
| Current ratio | 3.88 | 2.18 | 1.48 | 2.11 | 1.5 | |
| Interest coverage | -100.61 | -188.8 | 274.23 | -199.32 | -155.59 | |
| Income quality | 0.96 | 0.69 | 0.75 | 0.59 | 0.96 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0.78 | 1.32 | 0.38 | 0.29 | |
| Research and developement to revenue | 0 | 2.22 | 5.64 | 1.47 | 1.17 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | -0.02 | 0 | 0 | |
| Capex to depreciation | -0.34 | -0.09 | -0.81 | 0.03 | -0.1 | |
| Stock based compensation to revenue | 0 | 0.24 | 0.34 | 0.08 | 0.05 | |
| Graham number | 11.15 | 6.35 | 3.18 | 2.78 | 0.63 | |
| ROIC | -0.98 | -0.79 | -3.68 | -1.5 | 111.08 | |
| Return on tangible assets | -0.75 | -0.58 | -1.2 | -0.58 | -0.63 | |
| Graham Net | 2.17 | 1.05 | -0.13 | 0.21 | -0.19 | |
| Working capital | 57.24M | 35.62M | 18.63M | 37.68M | 15.12M | |
| Tangible asset value | 59.14M | 37.84M | 10.72M | 21.57M | -2.9M | |
| Net current asset value | 57.16M | 34.67M | 7.48M | 17.95M | -5.4M | |
| Invested capital | 0.17 | 0.31 | 0.74 | 0.23 | -0.45 | |
| Average receivables | 160.5K | 2.77M | 8.36M | 8.27M | 5.59M | |
| Average payables | 2.72M | 2.37M | 3.23M | 2.93M | 1.37M | |
| Average inventory | -160.5K | -2.77M | -2.77M | -1.3M | -1.3M | |
| Days sales outstanding | 0 | 96.79 | 338.02 | 39.44 | 33.12 | |
| Days payables outstanding | 0 | 14.84 | 24.51 | 2.51K | 3.69K | |
| Days of inventory on hand | 0 | -43.63 | 0 | -5.01K | 0 | |
| Receivables turnover | 0 | 3.77 | 1.08 | 9.26 | 11.02 | |
| Payables turnover | 0 | 24.59 | 14.89 | 0.15 | 0.1 | |
| Inventory turnover | 0 | -8.37 | 0 | -0.07 | 143K | |
| ROE | -1 | -1.06 | -6.75 | -2.04 | 10.26 | |
| Capex per share | -0.01 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.46 | 0.14 | 0.33 | 0.08 | 0.14 | |
| Net income per share | 0.13 | -0.19 | 0.03 | -0.14 | -0.09 | |
| Operating cash flow per share | 0.32 | -0.29 | -0.14 | 0.03 | -0.02 | |
| Free cash flow per share | 0.32 | -0.29 | -0.14 | 0.03 | -0.02 | |
| Cash per share | 0.6 | 0.46 | 0.61 | 0.56 | 0.54 | |
| Book value per share | 0.1 | -0.04 | 0.34 | 0.17 | 0.09 | |
| Tangible book value per share | 0.1 | -0.04 | 0.34 | 0.17 | 0.09 | |
| Share holders equity per share | 0.1 | -0.04 | 0.34 | 0.17 | 0.09 | |
| Interest debt per share | 0.02 | 0.02 | 0.02 | 0.06 | 0.05 | |
| Market cap | 55.64M | 54.37M | 99.87M | 101.83M | 85.07M | |
| Enterprise value | 4.18M | 22.96M | 52.9M | 55.94M | 40.76M | |
| P/E ratio | 1.17 | -1.02 | 9.86 | -2.06 | -2.6 | |
| Price to sales ratio | 1.37 | 5.32 | 3.84 | 13.37 | 6.69 | |
| POCF ratio | 1.99 | -2.59 | -9.16 | 36.08 | -52.06 | |
| PFCF ratio | 1.99 | -2.59 | -9.09 | 37.51 | -48.33 | |
| P/B Ratio | 6.14 | -18.72 | 3.72 | 6.61 | 10.58 | |
| PTB ratio | 6.14 | -18.72 | 3.72 | 6.61 | 10.58 | |
| EV to sales | 0.1 | 2.25 | 2.04 | 7.35 | 3.2 | |
| Enterprise value over EBITDA | 0.27 | -1.73 | 17.77 | -4.36 | -4.76 | |
| EV to operating cash flow | 0.15 | -1.09 | -4.85 | 19.82 | -24.94 | |
| EV to free cash flow | 0.15 | -1.09 | -4.81 | 20.61 | -23.16 | |
| Earnings yield | 0.21 | -0.25 | 0.03 | -0.12 | -0.1 | |
| Free cash flow yield | 0.5 | -0.39 | -0.11 | 0.03 | -0.02 | |
| Debt to equity | 0.18 | -0.45 | 0.04 | 0.29 | 0.54 | |
| Debt to assets | 0.02 | 0.03 | 0.01 | 0.07 | 0.07 | |
| Net debt to EBITDA | -3.38 | 2.37 | -15.78 | 3.58 | 5.18 | |
| Current ratio | 1.93 | 1.5 | 2.23 | 1.98 | 1.62 | |
| Interest coverage | 271.33 | -97.55 | 12.83 | -20.6 | 0 | |
| Income quality | 1.87 | 1.57 | -3.4 | -0.23 | 0.2 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.14 | 0.34 | 0.17 | 0.43 | 0.28 | |
| Research and developement to revenue | 0.49 | 1.96 | 0.72 | 2.25 | 1.36 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.01 | -0.04 | 0.08 | |
| Capex to revenue | 0 | 0 | 0 | -0.01 | -0.01 | |
| Capex to depreciation | -0.03 | -0.03 | -0.29 | 0.41 | -5.73 | |
| Stock based compensation to revenue | 0.02 | 0.07 | 0.02 | 0.1 | 0.06 | |
| Graham number | 0.56 | 0.41 | 0.5 | 0.73 | 0.43 | |
| ROIC | 1.22 | 50.16 | 0.1 | -0.53 | -0.5 | |
| Return on tangible assets | 0.18 | -0.28 | 0.03 | -0.18 | -0.13 | |
| Graham Net | -0.01 | -0.19 | 0.16 | 0.03 | -0.04 | |
| Working capital | 30.85M | 15.12M | 43.83M | 30.82M | 22.08M | |
| Tangible asset value | 9.07M | -2.9M | 26.84M | 15.41M | 8.04M | |
| Net current asset value | 6.11M | -5.4M | 24.59M | 9.67M | 2.27M | |
| Invested capital | 0.18 | -0.45 | 0.04 | 0.29 | 0.54 | |
| Average receivables | 4.94M | 5.44M | 15.83M | 15.65M | 4.17M | |
| Average payables | 3.67M | 2.85M | 2.71M | 2.94M | 2.78M | |
| Average inventory | 1 | 1 | 0.5 | 977K | 2.21M | |
| Days sales outstanding | 11.14 | 51.37 | 89.43 | 64.81 | 20.2 | |
| Days payables outstanding | 10.32K | 4.49K | 1.12K | 426.21 | 851.4 | |
| Days of inventory on hand | 0 | 0 | 0 | 438.55 | 573.72 | |
| Receivables turnover | 8.08 | 1.75 | 1.01 | 1.39 | 4.45 | |
| Payables turnover | 0.01 | 0.02 | 0.08 | 0.21 | 0.11 | |
| Inventory turnover | 37K | 29K | 0 | 0.21 | 0.16 | |
| ROE | 1.31 | 4.61 | 0.09 | -0.8 | -1.02 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
CDTX Frequently Asked Questions
What is Cidara Therapeutics, Inc. stock symbol ?
Cidara Therapeutics, Inc. is a US stock , located in San diego of Ca and trading under the symbol CDTX
What is Cidara Therapeutics, Inc. stock quote today ?
Cidara Therapeutics, Inc. stock price is $0.7299 today.
Is Cidara Therapeutics, Inc. stock public?
Yes, Cidara Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 695.76K
- Market Capitalization 73.4M
- Employee 73
- CEO Dr. Jeffrey L. Stein Ph.D.
- Headquarters San Diego,CA,US
- IPO Date 2015-04-15
-
Website
https://www.cidara.com 
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
